Objective To explore the impact of the“4+7”city drug centralized procurement policy implemented from April 1st,2019 on China’s pharmaceutical market and the differences between this pilot scheme and the first volum...Objective To explore the impact of the“4+7”city drug centralized procurement policy implemented from April 1st,2019 on China’s pharmaceutical market and the differences between this pilot scheme and the first volume procurement,so as to put forward some suggestions for this policy and improve the drug price formation mechanism.Methods The characteristics of the“4+7”volume procurement policy and its improvements were summarized through literature research,and the distribution of the winning enterprises in volume procurement was shown by the chart.Then the overall situation of pharmaceutical enterprises in China was analyzed.Results and Conclusion According to the main distribution of enterprises in the alliance region,we can see that the first round of bid-winning enterprises with 25 varieties are mainly distributed in the eastern coastal cities of Jiangsu,Zhejiang,Shandong,and Guangdong,which shows a trend of developing to provinces of Sichuan,Hubei,and Hunan.With the increase of volume procurement inland cities will be included in the future.This pilot scheme of volume procurement is a reform of the entire pharmaceutical industry.It has improved the market structure and promoted the transformation and upgrading of regional medicine representatives.The most important thing is to enable the public to better enjoy the benefits brought by the low-priced drugs.However,for some pharmaceutical enterprises and drug retail industry,it is a challenge.Therefore,it is necessary to improve the policy and strengthen market supervision and management.展开更多
目的对比“4+7”带量采购前后门诊胰岛素使用相关数据,分析带量采购政策对胰岛素使用的影响以及经济效应,为完善政策提供数据支撑。方法通过数字化医院信息管理系统(Hospital Information System,HIS)调取带量采购政策实施前后同期门诊...目的对比“4+7”带量采购前后门诊胰岛素使用相关数据,分析带量采购政策对胰岛素使用的影响以及经济效应,为完善政策提供数据支撑。方法通过数字化医院信息管理系统(Hospital Information System,HIS)调取带量采购政策实施前后同期门诊胰岛素的价格、使用量、销售金额、用药频度(Dynamic Delegation Discovery System,DDDs)、日均费用(Defined Daily Cost,DDC)等数据,进行统计分析整理出降幅、估计节省费用等评价指标。结果所有的胰岛素价格降幅为9.36%至71.81%,使用量下降9.55%,销售金额降低135.5万余元,不同胰岛素之间DDDs差距缩小,估计半年节省药费94.79万余元。结论胰岛素带量采购后,中标胰岛素联动非中标胰岛素降价,使日均费用大幅下降,减轻了糖尿病患者与医保的负担。展开更多
Objective To provide reference for improving drug procurement with target quantity in China.Methods Documents on drug centralized procurement such as the “Guidance on Drug Procurement with Target Quantity for 4+7 Cit...Objective To provide reference for improving drug procurement with target quantity in China.Methods Documents on drug centralized procurement such as the “Guidance on Drug Procurement with Target Quantity for 4+7 Cities” issued by National Healthcare Security Administration in November 2018 and “Notice on the National Organization of the Pilot Program for Drug Centralized Procurement and Use of Bidding Drugs” issued by the State Council were studied to summarize the mode and result of drug procurement with target quantity.Results and Conclusion Drug procurement with target quantity led by National Healthcare Security Administration solved some problems in the previous centralized drug procurement.For instance,quantity could not determine drug price,and medical institutions didn’t pay to pharmaceutical companies on time.However,this new mode may also arouse new problems such as procurement monopoly,drug shortage,drug quality and inhibition of innovation.展开更多
Objective To understand the effectiveness and problems of centralized drug procurement in China by analyzing the implementation of the“4+7”pilot work for centralized drug procurement in China.Methods The current sit...Objective To understand the effectiveness and problems of centralized drug procurement in China by analyzing the implementation of the“4+7”pilot work for centralized drug procurement in China.Methods The current situation and existing problems of drug procurement in China were analyzed through the literature research method.Results and Conclusion At present,good social benefits have been achieved for China’s drug procurement through pilot projects in several cities,but there are some serious problems.The proposed countermeasures will help to improve the procurement of pharmaceuticals in China.展开更多
文摘Objective To explore the impact of the“4+7”city drug centralized procurement policy implemented from April 1st,2019 on China’s pharmaceutical market and the differences between this pilot scheme and the first volume procurement,so as to put forward some suggestions for this policy and improve the drug price formation mechanism.Methods The characteristics of the“4+7”volume procurement policy and its improvements were summarized through literature research,and the distribution of the winning enterprises in volume procurement was shown by the chart.Then the overall situation of pharmaceutical enterprises in China was analyzed.Results and Conclusion According to the main distribution of enterprises in the alliance region,we can see that the first round of bid-winning enterprises with 25 varieties are mainly distributed in the eastern coastal cities of Jiangsu,Zhejiang,Shandong,and Guangdong,which shows a trend of developing to provinces of Sichuan,Hubei,and Hunan.With the increase of volume procurement inland cities will be included in the future.This pilot scheme of volume procurement is a reform of the entire pharmaceutical industry.It has improved the market structure and promoted the transformation and upgrading of regional medicine representatives.The most important thing is to enable the public to better enjoy the benefits brought by the low-priced drugs.However,for some pharmaceutical enterprises and drug retail industry,it is a challenge.Therefore,it is necessary to improve the policy and strengthen market supervision and management.
文摘Objective To provide reference for improving drug procurement with target quantity in China.Methods Documents on drug centralized procurement such as the “Guidance on Drug Procurement with Target Quantity for 4+7 Cities” issued by National Healthcare Security Administration in November 2018 and “Notice on the National Organization of the Pilot Program for Drug Centralized Procurement and Use of Bidding Drugs” issued by the State Council were studied to summarize the mode and result of drug procurement with target quantity.Results and Conclusion Drug procurement with target quantity led by National Healthcare Security Administration solved some problems in the previous centralized drug procurement.For instance,quantity could not determine drug price,and medical institutions didn’t pay to pharmaceutical companies on time.However,this new mode may also arouse new problems such as procurement monopoly,drug shortage,drug quality and inhibition of innovation.
基金Source of the project:Shenyang Pharmaceutical University 2019 college students innovation and pioneer projectLecturer support project for School of Business Administration,Shenyang Pharmaceutical University in 2019.
文摘Objective To understand the effectiveness and problems of centralized drug procurement in China by analyzing the implementation of the“4+7”pilot work for centralized drug procurement in China.Methods The current situation and existing problems of drug procurement in China were analyzed through the literature research method.Results and Conclusion At present,good social benefits have been achieved for China’s drug procurement through pilot projects in several cities,but there are some serious problems.The proposed countermeasures will help to improve the procurement of pharmaceuticals in China.
